Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system. It is the most common neurological disease in adults and women. The global multiple sclerosis drugs market is rapidly growing due to factors such as the growing prevalence of MS, significant unmet needs, and promising pipeline molecules.
The report titled "Multiple Sclerosis Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall multiple sclerosis drugs market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on molecule type (biologics and small molecules), route of administration (oral therapeutic drugs, parenteral therapeutic drugs), and different geographical regions.
Geographically, the global multiple sclerosis drugs market is studied for the following regional markets:
North America
US.
Canada
Europe
UK.
Germany
Rest of Europe
Asia-Pacific
China
Japan
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of LATAM
Middle East and Africa
GCC
the remainder of MEA
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario, pipeline analysis, and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global multiple sclerosis drugs market. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the competitive scenario of the global multiple sclerosis drugs market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global multiple sclerosis drugs market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global multiple sclerosis drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Based on molecule type, the global multiple sclerosis drugs market is segmented as follows:
Biologics
Small Molecule
Multiple sclerosis (MS) is an autoimmune disease in which the myelin sheaths of nerve cells in the brain and spinal cord are damaged. MS organizations have estimated that 2.3 million people are living with the disease worldwide. There is no cure for MS, but various disease management options are available on the market. These medications are used to slow disease progression and lower the relapse rate. For the purpose of the study, the market is segmented on the basis of molecule types, such as biologics and small molecules. Biologics was a significant revenue-generating segment in the base year of 2016. Biologics such as Avonex, Betaseron, CinnoVex, Extavia, Rebif, and Tysabri are widely used on the market. However, it is estimated that the small molecule segment will show the highest growth during the forecast period due to the expected launch of various oral formulations of small molecules such as ALKS-8700, OS-440, RPC-1063, ACT-128800, and BAF312.
Based on the route of administration, the global multiple sclerosis drugs market is segmented as follows:
Oral therapeutic drugs
Parenteral therapeutic drugs
Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system. It is the most common neurological disease of adults aged 20–40 and affects over 450,000 patients in the United States and over 3.5 million patients worldwide. Currently, there is no cure for MS, but various disease management options are available on the market. These medications are used to slow disease progression and lower the relapse rate. It is observed that in the base year 2016, parenteral therapeutic drugs were a major revenue-generating segment because some major parenteral drugs such as Avonex, Betaseron, Copaxone, Extavia, Glatopa, Plegridy, Rebif, and Zinbryta are driving the market's growth. However, it is estimated that oral therapeutics drugs will show significant market growth during the forecast period due to the expected launch of oral pipeline molecules such as OS-440, MD1003, Cladribine, CS-0777, Gilenya, RPC-1063, and ACT-128800.
For the purpose of this study, the global multiple sclerosis drugs market is categorized into:
North America
Europe
Asia Pacific
Latin America (LATAM)
Middle East and Africa (MEA)
In the base year 2016, North America dominated the multiple sclerosis drugs market, and it is estimated to show the fastest market growth during the forecast period. Some factors, such as the increasing incidence of MS, technological advances, an upsurge in funding by government agencies and private organizations in the healthcare system, and the higher cost of treatment medication, are prime factors that are fueling the growth of the multiple sclerosis drugs market in North America. According to the Multiple Sclerosis Foundation, more than 400,000 people in the United States and about 2.5 million people around the world have MS; about 200 new cases are diagnosed each week in the United States. MS is an expensive disease to treat; it is estimated that direct and indirect healthcare costs in the United States range from $8,528 to $54,244 per patient per year. Europe is the second-largest revenue-generating regional market for multiple sclerosis. The existence of a larger target population is driving market growth in Europe. The Multiple Sclerosis Foundation estimates that the incidence of MS is higher in colder climates; people of Northern European descent have the highest risk of developing MS, no matter where they live.
Frequently Asked Questions:
The market for Multiple Sclerosis Drugs is expected to reach US$ 27.38 Bn in 2025.
The Multiple Sclerosis Drugs market is expected to see significant CAGR growth over the coming years,at 6.3%.
The report is forecasted from 2017-2025.
The base year of this report is 2016.
Abbvie, Inc.,Acorda Therapeutics,Acorda Therapeutics, Inc.,Bayer HealthCare,Biogen are some of the major players in the global market.
